Division of Cardiovascular Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Department of Medicine II, Kansai Medical University, Hirakata, Japan.
J Endovasc Ther. 2020 Feb;27(1):77-85. doi: 10.1177/1526602819896293.
To identify intravascular ultrasound (IVUS) findings that predict midterm stent patency in femoropopliteal (FP) lesions. A retrospective analysis was undertaken of 335 de novo FP lesions in 274 consecutive patients (mean age 72.4±8.2 years; 210 men) who had IVUS assessment before and after successful stent implantation. The mean lesion length was 13.2±9.8 cm. The primary outcome was primary patency at 24 months, defined as freedom from major adverse limb event (MALE) and in-stent restenosis (ISR). MALE was defined as major amputation or any target lesion revascularization (TLR). ISR was defined by a peak systolic velocity ratio >2.4 by duplex ultrasonography. Logistic regression analyses were performed to identify independent predictors of stent patency at 24 months; the results are presented as the odds ratio (OR) and 95% confidence interval (CI). Receiver operator characteristic (ROC) curve analysis was performed to determine the optimal threshold for prediction of stent patency at 24 months. Over the 24-month follow-up, 18 (7%) patients died and 43 (15%) of 286 lesions were responsible for MALE (42 TLRs and 1 major amputation). Primary patency was estimated at 82.5% (95% CI 78.1% to 86.9%) at 12 months and 73.2% (95% CI 67.9% to 78.5%) at 24 months. Multivariable analysis revealed that longer lesion length (OR 0.89, 95% CI 0.82 to 0.97, p<0.01) was an independent predictor of declining patency, while cilostazol use (OR 3.45, 95% CI 1.10 to 10.78, p=0.03) and increasing distal reference external elastic membrane (EEM) area (OR 1.18, 95% CI 1.02 to 1.37, p=0.03) were associated with midterm stent patency. ROC curve analysis identified a distal reference EEM area of 29.0 mm as the optimal cut-point for prediction of 24-month stent patency (area under the ROC curve 0.764). Kaplan-Meier estimates of 24-month primary patency were 83.7% (95% CI 78.3% to 89.2%) in lesions with a distal EEM area >29.0 mm vs 53.1% (95% CI 42.9% to 63.3%) in those with a distal EEM area ≤29.0 mm (p<0.001). In FP lesions with a larger distal vessel area estimated with IVUS, stent implantation can be considered as a reasonable treatment option, with the likelihood of acceptable midterm results.
为了确定在股浅动脉(FP)病变中预测中期支架通畅性的血管内超声(IVUS)发现。对 274 例连续患者的 335 例新发 FP 病变进行了回顾性分析(平均年龄 72.4±8.2 岁;210 例男性),这些患者在成功植入支架前后均接受了 IVUS 评估。平均病变长度为 13.2±9.8cm。主要结局是 24 个月时的主要通畅率,定义为免于重大肢体不良事件(MALE)和支架内再狭窄(ISR)。MALE 定义为主要截肢或任何目标病变血运重建(TLR)。ISR 定义为双功超声检查的收缩期峰值速度比>2.4。进行逻辑回归分析以确定 24 个月时支架通畅的独立预测因素;结果以优势比(OR)和 95%置信区间(CI)表示。进行接收器操作特征(ROC)曲线分析以确定预测 24 个月支架通畅的最佳阈值。在 24 个月的随访期间,18 例(7%)患者死亡,286 例病变中有 43 例(15%)发生 MALE(42 例 TLR 和 1 例主要截肢)。12 个月时的主要通畅率估计为 82.5%(95%CI 78.1%至 86.9%),24 个月时为 73.2%(95%CI 67.9%至 78.5%)。多变量分析显示,较长的病变长度(OR 0.89,95%CI 0.82 至 0.97,p<0.01)是通畅率下降的独立预测因素,而西洛他唑的使用(OR 3.45,95%CI 1.10 至 10.78,p=0.03)和远端参考外膜弹性膜(EEM)面积的增加(OR 1.18,95%CI 1.02 至 1.37,p=0.03)与中期支架通畅率相关。ROC 曲线分析确定远端参考 EEM 面积为 29.0mm 为预测 24 个月支架通畅率的最佳切点(ROC 曲线下面积 0.764)。EEM 面积>29.0mm 的病变 24 个月时的主要通畅率估计为 83.7%(95%CI 78.3%至 89.2%),EEM 面积≤29.0mm 的病变为 53.1%(95%CI 42.9%至 63.3%)(p<0.001)。在通过 IVUS 估计远端血管面积较大的 FP 病变中,支架植入术可被视为合理的治疗选择,中期结果可能令人满意。